The Dechra Pharmaceuticals Board is proposing a final dividend of 29.39 pence per share (2020: 24.00 pence per share). Added to the interim dividend of 11.11 pence per share (2020: 10.29 pence per share), this brings the total dividend for the financial year ended 30 June 2021 to 40.50 pence per share (2020: 34.29 pence per share), representing 18.1% growth over the previous year.
Subject to shareholder approval at the Annual General Meeting to be held on 21 October 2021, the final dividend will be paid on 19 November 2021 to shareholders on the Register at 29 October 2021. The shares will become ex-dividend on 28 October 2021.
Other financial highlights include:
Revenue growth of 21.0% to £608.0 million.
Underlying operating profit increased by 29.2% to £162.2 million.
Underlying EBIT margin increased by 170 bps to 26.7%.
Underlying diluted EPS increased by 19.4%
